

Referenca

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. Sep 21 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368
2. Gayat E, et al. Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. *Eur J Heart Fail* 2018;20:345354.
3. Crespo-Leiro MG, et al., Heart Failure Association of the European Society of Cardiology. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HFLT): 1-year follow-up outcomes and differences across regions. *Eur J Heart Fail* 2016;18:613625.
4. McMurray JJ, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014;371:9931004.
5. Velazquez EJ, et al. PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. *N Engl J Med* 2019;380: 539548.
6. Wachter R, et al. TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. *Eur J Heart Fail* 2019;21:9981007.
7. McMurray JJV, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2019;381:19952008.
8. Packer M, et al., EMPERORReduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* 2020;383:14131424.
9. The CONSENSUS Trial Study Group. Enalapril for congestive heart failure. *N Engl J Med* 1987;317:13491351.
10. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. *JAMA* 1995;273:14501456.
11. Packer M, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. *Circulation* 1999;100:23122318.
12. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med* 1991;325:293302.
13. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 1999;353:20012007.
14. Packer M, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med* 1996;334:13491355.
15. Packer M, et al., Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001;344:16511658.
16. Hjalmarson A, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. *JAMA* 2000;283:12951302.
17. Packer M, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol

prospective randomized cumulative survival (COPERNICUS) study. *Circulation* 2002;106:2194-2199.

18. Flather MD, et al. SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005;26:215-225.
19. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999;353:913.
20. Fowler MB. Effects of beta blockers on symptoms and functional capacity in heart failure. *Am J Cardiol* 1997;80:55L-58L.
21. Willenheimer R, et al. CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. *Circulation* 2005;112:2426-2435.
22. Kotecha D, et al. Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. *Lancet* 2014;384:2235-2243.
23. Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999;341:709-717.
24. Zannad F, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011;364:1121.
25. Seferovic JP, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. *Lancet Diabetes Endocrinol* 2017;5:333-340.
26. Damman K, et al. Renal effects and associated outcomes during angiotensin neprilysin inhibition in heart failure. *JACC Heart Fail* 2018;6:489-498.
27. Desai AS, et al. Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF Trial. *JAMA Cardiol* 2017;2:7985.
28. Vardeny O, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. *Eur J Heart Fail* 2019;21:337-341.
29. Vardeny O, et al. Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). *Circ Heart Fail* 2018;11:e004745.
30. Morrow DA, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF trial. *Circulation* 2019;139:2285-2288.
31. Kosiborod MN, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. *Circulation* 2020; 141:9099.

32. Butler J, et al. EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. *Eur Heart J* 2021; 42: 12031212.
33. Zannad F, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPERORReduced and DAPA-HF trials. *Lancet* 2020; 396:819829.
34. Jackson AM, et al. Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. *Circulation* 2020;142:10401054.
35. Bhatt DL, et al. SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. *N Engl J Med* 2021; 384:117128.
36. Faris R, et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. *Int J Cardiol* 2002; 82:149158.
37. Granger CB, et al. Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003; 362:772776.
38. Swedberg K, et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet* 2010; 376:875885.
39. Swedberg K, et al. SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. *J Am Coll Cardiol* 2012; 59:19381945.
40. Armstrong PW, et al. VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2020; 382:18831893.
41. Taylor AL, et al. African - American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. *N Engl J Med* 2004;351: 20492057.
42. Cohn JN, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. *N Engl J Med* 1986;314: 15471552. ESC Guidelines 3699
43. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997; 336:525533.
44. Mullens W, et al. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J Heart Fail* 2019;21: 137155.
45. Rohde LE, et al. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial. *Eur Heart J* 2019; 40: 36053612.
46. Bohm M, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. *Clin Res Cardiol* 2013;102: 1122.
47. Cohn JN, et al. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. *N Engl J Med* 2001;345: 16671675.
48. Ouyang AJ, Lv YN, Zhong HL, Wen JH, Wei XH, Peng HW, Zhou J, Liu LL. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. *Am J Cardiol* 2015;115: 901906.
49. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. *Eur Heart J* 2015;36: 18311838.

50. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend J, Kotecha D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. *BMJ* 2015;351:h4451.
51. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP, RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. *N Engl J Med* 2010;362: 1363-1373.
52. Bavishi C, Khan AR, Ather S. Digoxin in patients with atrial fibrillation and heart failure: a meta-analysis. *Int J Cardiol* 2015;188: 99-101.
53. Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, Borowsky LH, Harrison TN, Singer DE, Go AS. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. *Circ Arrhythm Electrophysiol* 2015; 8:495-8.
54. Washam JB, et al, ROCKET Steering Committee and Investigators. Digoxin use in patients with atrial fibrillation AF and adverse cardiovascular outcomes: retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin a K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). *Lancet* 2015;385: 2363-2370.
55. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. *JAMA* 2003; 289:871-878.
56. Adams KF, Jr., et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group trial: a retrospective analysis. *J Am Coll Cardiol* 2005; 46: 497-504.
57. Bavendiek U, et al., DIGIT-HF Investigators and Committees. Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. *Eur J Heart Fail* 2019; 21:676-684.
58. Teerlink JR, et al. GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. *N Engl J Med* 2021; 384:1051-16.
59. Verquvo Summary of product characteristics July 2021
60. Gheorghide M, Greene SJ, Butler J, et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. *Jama*. Dec 1 2015;314(21):2251-62. doi:10.1001/jama.2015.15734
61. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. *J Am Coll Cardiol*. 1992;20:248-54. [http://dx.doi.org/10.1016/0735-1097\(92\)90167-L](http://dx.doi.org/10.1016/0735-1097(92)90167-L)
62. Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. *Curr Heart Fail Rep*. 2004;1:45-50. <http://dx.doi.org/10.1007/s11897-004-0024-5>
63. Wagman G, Fudim M, Kosmas CE, Panni RE, Vittorio TJ. The neurohormonal network in the RAAS can bend before breaking. *Curr Heart Fail Rep*. 2012;9:81. <https://doi.org/10.1007/s11897-012-0091-y>
64. Okwuosa IS, Princewill O, Nwabueze C, Mathews L, Hsu S, Gilotra NA, Lewsey S, Blumenthal RS, Russell SD. The ABCs of managing systolic heart failure: past, present, and future. *Cleve Clin J Med*. 2016;83:753-65. <http://dx.doi.org/10.3949/ccjm.83a.16006>

65. Ponikowski P, et al. Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2016;18:891–975. <http://dx.doi.org/10.1002/ejhf.592>
66. Williams SG, Jackson M, Cooke GA, Barker D, Patwala A, Wright DJ, Albuoaini K, Tan LB. How do different indicators of cardiac pump function impact upon the long-term prognosis of patients with chronic heart failure? *Am Heart J*. 2005;150:983. e1–e6. <http://dx.doi.org/10.1016/j.ahj.2005.08.018>
67. Teerlink JR, Metra M, Zacà V, Sabbah HN, Cotter G, Gheorghide M, Cas LD. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. *Heart Fail Rev*. 2009;14:243–53. <http://dx.doi.org/10.1007/s10741-009-9153-y>
68. Tariq S, Aronow WS. Use of inotropic agents in treatment of systolic heart failure. *Int J Mol Sci*. 2015;16:29060–8. <http://dx.doi.org/10.3390/ijms161226147>
69. Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. *Circ Heart Fail* 2010;3:522–527.
70. Malik FI, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. *Science*. 2011;331:1439–43. <http://dx.doi.org/10.1126/science.1200113>
71. Sun YB, Irving M. The molecular basis of the steep force-calcium relation in heart muscle. *J Moll Cell Cardiol*. 2010;48:859–65. <http://dx.doi.org/10.1016/j.yjmcc.2009.11.019>
72. Sweeney HL, Houdusse A. Structural and functional insights into the myosin motor mechanism. *Annu Rev Biophys*. 2010;39:539–57 <http://dx.doi.org/10.1146/annurev.biophys.050708.133751>
73. Morgan BP, et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin. *ACS Med Chem Lett*. 2010;1:472–7. <http://dx.doi.org/10.1021/ml100138q>
74. Winkelmann DA, et al. Structural basis for drug-induced allosteric changes to human b-cardiac myosin motor activity. *Nat Commun*. 2015;6:7974. <http://dx.doi.org/10.1038/ncomms8974>
75. Liu Y, White HD, Belknap B, Winkelmann DA, Forgacs E. Omecamtiv Mecarbil modulates the kinetic and motile properties of porcine β -cardiac myosin. *Biochemistry*. 2015;54:1963–75. <http://dx.doi.org/10.1021/bi5015166>
76. Spudich JA. Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. *Biophys J*. 2014;106:1236–49. <http://dx.doi.org/10.1016/j.bpj.2014.02.011>
77. Registrational Study with Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure with Reduced Ejection Fraction (GALACTIC-HF). *ClinicalTrials.gov* Identifier: NCT02678923. Available at: <https://clinicaltrials.gov/ct2/show/results/NCT02929329>
78. Teerlink JR, Diaz R, Felker GM, et al. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. *Eur J Heart Fail* 2020 September 27 (Epub ahead of print).
79. Teerlink JR, Felker GM, McMurray JJ, et al. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. *Lancet* 2016;388:2895–2903.